Physician profile
Ashraf Jamil
NPI 1053793232
$2,232.90
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $56.88 · 2021: $318 · 2022: $551 · 2023: $557 · 2024: $448 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $828.36 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $403.41 | 2020-2024 | Eliquis, Camzyos |
| Gilead Sciences, INC. | $206.97 | 2021-2024 | Veklury |
| Novartis Pharmaceuticals Corporation | $186.96 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.78 | 2022-2025 | Lifevest |
| Abbvie INC. | $124.19 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.40 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $80.93 | 2021-2023 | Farxiga |
| Pfizer INC. | $42.56 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.13 | 2022-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $28.98 | 2023 | Inpefa |
| W. L. Gore & Associates, INC. | $19.08 | 2021 | |
| Baxter Healthcare | $18.34 | 2023 | Hillrom - Life 2000 Ventilation System |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.